Home LiteratureArticle Details
PMID: 19011565 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

The American journal of surgical pathology ·Vol. 33 ·No. 3 ·2009-03-00 ·Pages 376-83

Roh MH, Kindelberger D, Crum CP

Abstract

Pelvic serous cancer is a diverse disease, and the assignment of primary site -- ovarian, tubal, or peritoneal -- is often problematic. Recent studies indicate that a proportion of these tumors arise from the distal fallopian tube, originating as serous tubal intraepithelial carcinoma (STIC). This study examined the relationship of 2 parameters for assigning origin -- endosalpingeal involvement and dominant ovarian mass -- in the context of STIC. Endometrioid carcinomas served as a reference. Eighty-seven consecutive pelvic serous cancers in which the tubes and ovaries were completely examined (SEE-FIM protocol) were analyzed. The presence of a dominant ovarian mass (DOM+), involvement of the fimbrial mucosa (FIM+), and STIC were correlated. In addition, tumor categories were compared with respect to PAX8, p73, p53, and p16 immunohistochemistry. Of the 27 DOM+ cases, 13 (48%) were FIM+ and a STIC was present in 3 (11%). Of the 60 DOM(-) cases, 48 (78%) were FIM+ and 28 (45%) harbored a STIC. In 92% of all cases, tumor distribution was extensive with bilateral ovarian and extraovarian peritoneal involvement. All tumor categories were immunophenotypically similar. In contrast, DOM+, FIM+, and STIC were found in 81%, 19%, and 0% of ovarian endometrioid carcinomas. In conclusion, there is a significant inverse relationship between DOM+ and STIC (P=0.001), indicating both parameters are of value in grouping pelvic serous carcinomas more likely to be ovarian [DOM+/FIM(-)] versus fimbrial [DOM(-)/STIC], and ovarian or peritoneal surface (DOM-/FIM-) in origin. Nevertheless, the shared immunophenotype suggests a common cell of origin for all categories, irrespective of site.

MeSH Terms
Biomarkers, Tumor/analysis Carcinoma in Situ/metabolism,pathology Cystadenocarcinoma, Serous/metabolism,pathology Fallopian Tube Neoplasms/metabolism,pathology Female Humans Immunohistochemistry Immunophenotyping Ovarian Neoplasms/metabolism,pathology Peritoneal Neoplasms/metabolism,pathology
Chemicals
Biomarkers, Tumor
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Roh Michael H
Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Kindelberger David
Crum Christopher P
Article Info
Journal
The American journal of surgical pathology
Abbr.
Am J Surg Pathol
ISSN
1532-0979
Published
2009-03-00
Pages
376-83
Language
English
Region
United States
NLM ID
7707904
Subset
IM
Grants
NCI NIH HHS · 1 R21 CA124688 · United States
NCI NIH HHS · P50 CA10500 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]